Table 4.
Prognosis variation of adult T‐cell leukemia/lymphoma (ATL) by subtype
| Items related to prognosis | Acute (n = 391) | Lymphoma (n = 192) | Chronic (n = 106) | Among chronic subtype | Smoldering (n = 81) | Among smoldering subtype | ||
|---|---|---|---|---|---|---|---|---|
| Unfavorable (n = 71) | Favorable (n = 33) | Skin lesion positive (n = 43) | Skin lesion negative (n = 37) | |||||
| Follow‐up duration for all, median (IQR), d | 210 (101‐468) | 252 (131‐619) | 631 (217‐1467) | 425 (183‐1467) | 1438 (612‐1607) | 968 (386‐1693) | 662 (394‐1701) | 1494 (370‐1692) |
| Follow‐up duration only for alive patients, median (IQR), d | 1354 (110‐1784) | 1440 (106‐1688) | 1491 (535‐1761) | 1543 (267‐1878) | 1481 (1060‐1690) | 1561 (419‐1744) | 1379 (293‐1731) | 1594 (1202‐1757) |
| No. of deaths (proportion of each total) | 297 (76.0%) | 139 (72.4%) | 61 (57.5%) | 47 (66.2%) | 13 (39.4%) | 30 (37.0%) | 18 (41.9%) | 11 (29.7%) |
| MST (95%CI), d | 252 (214‐301) | 305 (244‐364) | 778 (599‐1264) | 572 (339‐690) | 1937 (1137‐1937) | 1851 (1275‐NR) | 1739 (594‐NR) | NR |
| 4‐year survival rate (95%CI), % | 16.8 (13.2‐21.2) | 19.6 (14.2‐26.4) | 37.4 (28.2‐47.8) | 26.6 (17.1‐38.9) | 62.1 (43.4‐77.7) | 59.8 (47.6‐70.9) | 54.3 (37.6‐70.0) | 68.5 (50.6‐82.1) |
Abbreviations: CI, confidence interval; IQR, interquartile range; MST, median survival time; NR, not reached.